Diabetes & Endocrinology
Latest news
609 articles · 20 / page
Synergistic Protection: Combining GLP-1 Receptor Agonists with Lifestyle Habits Slashes Cardiovascular Risk in Type 2 Diabetes
A massive cohort study of nearly 100,000 veterans reveals that while GLP-1 receptor agonists significantly reduce MACE, the combination with a healthy lifestyle offers a 43% lower risk, emphasizing the need for integrated cardiometabolic ca
Beyond the Binary: The Evolving Consensus on the Spectrum of Primary Aldosteronism and Cardiovascular Risk
Recent data from the ARIC study and emerging expert consensus are redefining primary aldosteronism. Rather than a rare, all-or-nothing condition, it is now viewed as a broad spectrum where even subclinical elevations significantly increase
Beyond Mandatory Resection: Active Surveillance Proves Safe for RAS-Positive Thyroid Nodules
A new study suggests that isolated RAS mutations in Bethesda III and IV thyroid nodules do not always require surgery. With a 34% malignancy rate and low growth incidence, active surveillance emerges as a viable, safe alternative for approp
Beyond Haploinsufficiency: How Nonsense-Mediated Decay Escape Redefines MODY Diagnosis and Identifies Novel INS Variants
A systematic analysis reveals that the pathogenicity of loss-of-function variants in MODY genes is gene-specific and dependent on nonsense-mediated decay status. Crucially, NMD-escape variants in the INS gene represent a novel, clinically d
Oxygen-Guided Success: A New Frontier in Adrenal Venous Sampling for Primary Aldosteronism
Researchers have discovered that measuring oxygen partial pressure (pO2) can significantly improve the accuracy and speed of Adrenal Venous Sampling, providing a cost-effective tool for diagnosing Primary Aldosteronism.
SGLT2 Inhibitors Reduce Gout-Related Medication Burden in Patients with Type 2 Diabetes
A large-scale target trial emulation study demonstrates that SGLT2 inhibitors significantly reduce the initiation of allopurinol and the use of anti-inflammatory medications in patients with comorbid gout and type 2 diabetes, offering a pot
Precision Risk Stratification in Cushing’s Disease: Integrating USP8 Genotype and Tumor Size to Predict Long-Term Recurrence
An international cohort study demonstrates that combining USP8 genotype with tumor size significantly improves the prediction of recurrence in Cushing’s disease, identifying high-risk patients even among those with low postoperative cortiso
Orforglipron Demonstrates Superior HbA1c Reduction Over Oral Semaglutide in Type 2 Diabetes: Results from the ACHIEVE-3 Trial
The ACHIEVE-3 phase 3 trial demonstrates that orforglipron, a novel non-peptide oral GLP-1 receptor agonist, provides superior glycemic control compared to oral semaglutide in adults with type 2 diabetes, despite a higher frequency of gastr
SGLT2 Inhibitors Offer Potent Protection Against Contrast-Induced Kidney Injury During Coronary Intervention
A large-scale registry study reveals that preprocedural SGLT2 inhibitor use significantly reduces the risk of contrast-associated acute kidney injury in diabetic patients undergoing PCI, suggesting a major shift in peri-procedural managemen
Insulin Resistance Blunts LVAD-Mediated Myocardial Recovery by Impairing the Pentose Phosphate Pathway
Obesity-induced insulin resistance hinders heart failure recovery post-LVAD by disrupting the pentose phosphate pathway. A new study in Circulation suggests insulin sensitizers could restore cardiac repair mechanisms in obese patients.
Women Achieve Greater Weight Loss With GLP-1 Receptor Agonists: A Comprehensive Meta-Analysis of Treatment Heterogeneity
A systematic review and meta-analysis of 64 randomized trials reveals that GLP-1 receptor agonists lead to significantly higher weight loss in women (10.9%) compared to men (6.8%), while maintaining consistent efficacy across various ages,
Heart Failure Prevention in Type 2 Diabetes: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT-2 and DPP-4 Inhibitors
A large-scale target trial emulation demonstrates that GLP-1RAs significantly reduce heart failure hospitalization risks compared to DPP-4 inhibitors and provide comparable protection to SGLT-2 inhibitors in routine clinical practice.
Short-Course Romosozumab Followed by Denosumab Is Non-Inferior to Standard 12-Month Regimen for Postmenopausal Osteoporosis
The LIDA trial demonstrates that a 3-month abbreviated course of romosozumab followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially reducing treatment costs and injec
Proactive Pharmacist Outreach Slashes Hypoglycemia Risk and Optimizes Prescribing in High-Risk Type 2 Diabetes
This randomized clinical trial demonstrates that proactive pharmacist outreach using evidence-based algorithms significantly improves prescribing safety and reduces emergency hypoglycemia events in high-risk patients with type 2 diabetes wi
Long-Term Benfotiamine Treatment Fails to Improve Diabetic Polyneuropathy: Insights from the BOND Randomized Controlled Trial
The 12-month BOND study found that high-dose benfotiamine (600 mg daily) did not significantly improve corneal nerve fiber length or other neurophysiological markers in patients with type 2 diabetes and symptomatic polyneuropathy, despite s
Produce Prescriptions Alone Fail to Improve Diabetes Outcomes: Lessons from a Major Pragmatic Trial
A large-scale randomized trial reveals that monthly produce subsidies do not significantly improve HbA1c or reduce healthcare utilization in food-insecure diabetes patients, suggesting that ‘Food is Medicine’ initiatives require more than j
Indigenous American Ancestry and Type 2 Diabetes: A Genomic Perspective on Mexico’s Public Health Crisis
A massive study of 134,548 Mexicans reveals that Indigenous American genomic ancestry is a potent, independent risk factor for type 2 diabetes and prediabetes, highlighting an urgent need for population-specific preventive healthcare strate
Semaglutide Mitigates Cardiometabolic Risk in Early-Stage Schizophrenia: Insights from a Randomized Clinical Trial
A landmark RCT demonstrates that adjunctive semaglutide significantly improves glycemic control and induces substantial weight loss in individuals with schizophrenia spectrum disorders treated with second-generation antipsychotics, potentia
SGLT2 Inhibitors for All? Meta-Analysis Confirms Broad Clinical Benefits Regardless of Diabetes or Albuminuria Levels
A large-scale meta-analysis reveals that SGLT2 inhibitors significantly reduce kidney disease progression, AKI, and hospitalizations in patients with CKD, independent of diabetes status or baseline albuminuria.
SGLT2 Inhibitors Provide Robust Kidney Protection Across All Stages of CKD and Levels of Albuminuria: Evidence from the SMART-C Meta-Analysis
A meta-analysis of over 70,000 participants confirms that SGLT2 inhibitors significantly reduce chronic kidney disease progression regardless of baseline kidney function or albuminuria levels, supporting their use even in patients with Stag
Browse by specialty
Open language-specific specialty feeds and department pages.